Fetzima and Mobic drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Fetzima and Mobic. Common interactions include fall among females and atrial fibrillation among males.

The phase IV clinical study analyzes what interactions people who take Fetzima and Mobic have. It is created by eHealthMe based on reports of 15 people who take Fetzima and Mobic from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Aug, 09, 2022

15 people who take Fetzima and Mobic together, and have interactions are studied.


What is Fetzima?

Fetzima has active ingredients of levomilnacipran hydrochloride. It is often used in depression. eHealthMe is studying from 1,527 Fetzima users for its effectiveness, alternative drugs and more.

What is Mobic?

Mobic has active ingredients of meloxicam. It is often used in arthritis. eHealthMe is studying from 24,944 Mobic users for its effectiveness, alternative drugs and more.

Number of Fetzima and Mobic reports submitted per year:

Fetzima and Mobic drug interactions.

Common Fetzima and Mobic drug interactions by gender *:

female:

  1. Fall
  2. Cubital tunnel syndrome
  3. Diabetes mellitus
  4. Drug hypersensitivity
  5. Dry mouth
  6. Dysphonia
  7. Fatigue
  8. Gastric disorder
  9. Headache
  10. Hyperglycaemia

male:

  1. Atrial fibrillation

Common Fetzima and Mobic drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Aggression
  2. Knee arthroplasty

40-49:

  1. Neuralgia
  2. Stomatitis
  3. Swollen tongue
  4. Type 2 diabetes mellitus
  5. Fall
  6. Upper limb fracture
  7. Aphthous ulcer
  8. Atrial fibrillation
  9. Diabetes mellitus
  10. Dry mouth

50-59:

n/a

60+:

  1. Hyperglycaemia
  2. Hyperlipidaemia
  3. Periodic limb movement disorder

Common conditions people have *:

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 12 people, 80.00%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 7 people, 46.67%
  3. Pain: 2 people, 13.33%
  4. Migraine (headache): 2 people, 13.33%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 13.33%
  6. Thyroid Diseases: 1 person, 6.67%
  7. Stress And Anxiety: 1 person, 6.67%
  8. Sinusitis (inflammation of sinus): 1 person, 6.67%
  9. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 6.67%
  10. Ligament Sprain (ligament stretched): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Fetzima and Mobic?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Fetzima and Mobic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Fetzima interactions:

Browse all interactions between Fetzima and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Mobic interactions:

Browse all interactions between Mobic and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on levomilnacipran hydrochloride and meloxicam (the active ingredients of Fetzima and Mobic, respectively), and Fetzima and Mobic (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: